- Preliminary unaudited Q4 and Full Year 2025 net Attruby® product revenue of $146.0 million and$362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, driven by differentiated clinical data and growing real-world confidence - New TTR amyloid depleter antibody program announced to explore the potential of ATTR-CM disease reversal; progra ...